Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial - 04/06/15
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Aim |
This study compared the efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose (FPG) as single-pill combinations (SPCs) with metformin.
Methods |
The randomized crossover, open-label, active-controlled study design assessed the FPG-lowering abilities of a vildagliptin/metformin (50/1000mg twice daily) SPC compared with a sitagliptin/metformin (50/1000mg twice daily) SPC after 2 weeks of treatment in 99 type 2 diabetes patients uncontrolled by stable metformin therapy (1000–2000mg/day).
Results |
The change in FPG from baseline to day 14 was significantly greater (P<0.02, Wilcoxon) with vildagliptin [–21.9mg/dL (SD 27.0)] than with sitagliptin [–14.5mg/dL (SD 23.0)]. After 14 days of treatment, the mean FPG was 137.8mg/dL (SD 28.5) with vildagliptin and 140.1mg/dL (SD 26.5) with sitagliptin (P<0.05, Wilcoxon).
Conclusion |
Both of these DPP-4 inhibitors, given as SPCs twice daily with metformin, lowered FPG after 14 days of treatment. However, vildagliptin produced a significantly greater reduction in FPG vs baseline compared with sitagliptin, which may translate into clinical relevance.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Type 2 diabetes mellitus, Vildagliptin, Sitagliptin, Fasting plasma glucose, Dipeptidyl peptidase inhibitors
Mappa
Vol 41 - N° 3
P. 244-247 - giugno 2015 Ritorno al numero
Articolo precedente
- Screening for dysglycaemia during pregnancy: Proposals conciliating International Association of Diabetes and Pregnancy Study Group (IADPSG) and US National Institutes of Health (NIH) panels
- E. Cosson, P. Valensi, L. Carbillon
- Increased TSH in obesity: Evidence for a BMI-independent association with leptin
- C. Bétry, M.A. Challan-Belval, A. Bernard, A. Charrié, J. Drai, M. Laville, C. Thivolet, E. Disse
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.